Citas bibligráficas
Rodríguez, L., (2024). Efecto de la trabeculoplastia láser selectiva comparado con antiglaucomatosos tópicos como tratamiento de primera línea del glaucoma primario de ángulo abierto: Revisión Sistemática y Metaanálisis [Tesis, Universidad Privada Antenor Orrego]. https://hdl.handle.net/20.500.12759/33491
Rodríguez, L., Efecto de la trabeculoplastia láser selectiva comparado con antiglaucomatosos tópicos como tratamiento de primera línea del glaucoma primario de ángulo abierto: Revisión Sistemática y Metaanálisis [Tesis]. PE: Universidad Privada Antenor Orrego; 2024. https://hdl.handle.net/20.500.12759/33491
@misc{renati/378535,
title = "Efecto de la trabeculoplastia láser selectiva comparado con antiglaucomatosos tópicos como tratamiento de primera línea del glaucoma primario de ángulo abierto: Revisión Sistemática y Metaanálisis",
author = "Rodríguez Salazar, Loui Sofía",
publisher = "Universidad Privada Antenor Orrego",
year = "2024"
}
To compare the effect of selective laser trabeculoplasty and topical antiglaucoma medications (AGMs) as first-line treatment on intraocular pressure, adverse effects, and quality of life in patients with primary open-angle glaucoma (POAG). Methods: A systematic review was conducted using data from available randomized clinical trials in databases such as PubMed, Scopus, Cochrane Library, Embase, and Web of Science. Studies comparing clinical effects between SLT and AGMs in patients with POAG were included. The quality of the studies was evaluated, and relevant data were extracted. Results: The review included 11 randomized clinical trials with a total of 717 patients. The results showed that the reduction in intraocular pressure (IOP) was lower in the AGM group compared to the SLT group at 1 week, 4 weeks and after 3 months of treatment. However, the difference after 3 months was clinically small (-1.09; 95% CI [-1.96, -0.21]) and furthermore no difference was found in the percentage reduction or the goal of reducing IOP >20% between both treatment modalities. The incidence of adverse effects showed no significant difference between SLT and AGMs. Conclusions: AGM reduces IOP less than SLT. After 3 months, it would be an option to consider in case of difficulties with access and/or adherence to antiglaucomatous treatment. The safety of both treatments is similar.
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons